EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
BlueScope Steel Shares Slip After Board Rejects A$13.2 Billion Takeover Bid 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
CAMBRIDGE, Mass., Oct. 25, 2017 -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will host a conference call and live webcast on Wednesday, November 1, 2017 at 8:00 a.m. ET to report its third quarter 2017 financial results and discuss recent clinical development and corporate activities.
A live webcast can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. The conference call can be accessed by dialing 1-877-377-7098 (domestic) or 1-631-291-4547 (international) and referring to conference ID 99771605. The webcast will be archived and made available for replay on the company's website beginning approximately two hours after the event.
About Agios
Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has an approved oncology precision medicine and multiple first-in-class investigational therapies in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit the company's website at www.agios.com.
Agios Pharmaceuticals: Renee Leck, 617-649-8299 Senior Manager, Investor & Public Relations [email protected]
